KIORA PHARMACEUTICALS INC — SEC Form D Filing
KIORA PHARMACEUTICALS INC filed an SEC Form D on April 21, 2026, reporting $5.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 21, 2026
- Amount reported
- $5.00M
- Round stage
- Seed
- Industry
- Pharmaceuticals
- Website
- https://kiorapharma.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
There are retinal diseases that threaten vision and have limited or no effective therapies available.
Solution
The company develops small molecule therapies targeting critical pathways in retinal diseases to slow, stop, or restore vision loss.
Verdict
Investors said yes at this moment due to the high unmet need for effective therapies in retinal diseases, not because Kiora Pharmaceuticals had defined competitive advantages. They were implicitly betting on the potential efficacy of the company's novel small molecule therapies to address significant market gaps in vision restoration. However, the lack of clarity around the buyer and budget owner implies limited durability for this narrative, as the reliance on future clinical results could jeopardize sustained interest.
Source: SEC EDGAR Form D filing